Array BioPharma announces FDA acceptance to review new melanoma drug applications

Array BioPharma announces FDA acceptance to review new melanoma drug applications

BOULDER -- Array BioPharma (Nasdaq: ARRY) announced the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Applications (NDAs) to support use of the combination of... Read More

Wednesday September 13, 2017 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, encorafenib, binimetinib

Array BioPharma submits New Drug Applications to FDA for binimetinib and encorafenib in advanced melanoma treatment

Array BioPharma submits New Drug Applications to FDA for binimetinib and encorafenib in advanced melanoma treatment

BOULDER -- Array BioPharma (Nasdaq:ARRY) today announced the submission of two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) to support use of the combination of... Read More

Wednesday July 5, 2017 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, binimetinib, encorafenib

Array BioPharma and Bristol-Myers Squibb announce strategic research collaboration

Array BioPharma and Bristol-Myers Squibb announce strategic research collaboration

BOULDER andNEW YORK CITY -- Array BioPharma (Nasdaq: ARRY) and Bristol-Myers Squibb Company (NYSE:BMY) announced the companies have entered into a clinical research collaboration to investigate... Read More

Thursday June 1, 2017 0 comments Tags: Boulder, Array BioPharma, Bristol-Myers Squibb, Ron Squarer, Fouad Namouni

Array BioPharma announces strategic collaboration with Merck

Array BioPharma announces strategic collaboration with Merck

BOULDER -- Array BioPharma Inc .(Nasdaq: ARRY) announced it has entered into a clinical trial collaboration agreement with Merck (known as MSD outsidethe United StatesandCanada) to investigate... Read More

Tuesday May 9, 2017 0 comments Tags: Boulder, Array BioPharma, Merck, Ron Squarer, binimetinib, KEYTRUDA

Array BioPharma, Pierre Fabre announce positive results for cancer drug

Array BioPharma, Pierre Fabre announce positive results for cancer drug

BOULDER -- Array BioPharma (Nasdaq: ARRY) and Pierre Fabre today jointly announced top-line results from Part 1 of the Phase 3 COLUMBUS ( Co mbined L GX818 U sed with M EK162 in B RAF... Read More

Monday September 26, 2016 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, Keith T. Flaherty, encorafenib, binimetinib, Frederic Duchecesne, COLUMBUS

Array BioPharma appoints Jason Haddock CFO

Array BioPharma appoints Jason Haddock CFO

BOULDER -- Array BioPharma (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted... Read More

Thursday July 28, 2016 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, Jason Haddock, David Horin

Array BioPharma submits New Drug Application for binimetinib to FDA

Array BioPharma submits New Drug Application for binimetinib to FDA

BOULDER -- Array BioPharma (Nasdaq:ARRY) announced it submitted a New Drug Application (NDA) to the FDA for binimetinib in patients with advanced NRAS -mutant melanoma. The submission is... Read More

Friday July 1, 2016 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, binimetinib

Array BioPharma partners with Pierre Fabre to globally develop and market cancer drugs

Array BioPharma partners with Pierre Fabre to globally develop and market cancer drugs

BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) and France-based Pierre Fabre are collaborating to globally develop and commercialize Arrays late-stage novel oncology products, binimetinib and... Read More

Tuesday November 17, 2015 0 comments Tags: Boulder, Array BioPharma, Pierre Fabre, Ron Squarer, binimetinib, encorafenib